Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Mazzotta, Celestina ^a   Romano, Eloisa ^a   Bruni, Cosimo ^a   Manetti, Mirko ^b   Lepri, Gemma ^a   Bellando Randone, Silvia ^a   Blagojevic, Jelena ^a   Ibba Manneschi, Lidia ^b   Matucci Cerinic, Marco ^a   Guiducci, Serena ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; PLEXIN; PLEXIN D1; SEMAPHORIN; SEMAPHORIN 3E; UNCLASSIFIED DRUG; VASCULOTROPIN; NERVE CELL ADHESION MOLECULE; PLXND1 PROTEIN, HUMAN; SEMA3E PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL TONE; CELL ADHESION; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGER ULCER; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; BLOOD; BLOOD VESSEL; CELL CULTURE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN; VASCULARIZATION;

ADULT; AGED; BLOOD VESSELS; BLOTTING, WESTERN; CELL ADHESION MOLECULES, NEURONAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SEMAPHORINS; SIGNAL TRANSDUCTION; SKIN;

EID: 84939494168     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0749-4     Document Type: Article

References (41)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587-95.
2. Wigley FM. Raynaud's Phenomenon. N Engl J Med. 2002;347:1001-8.
3. Noel B. Pathophysiology and classification of the vibration white finger. Int Arch Occup Environ Health. 2000;73:150-5.
4. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol. 1992;19:580-96.
5. Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol. 2005;17:752-60.
6. Herrick AL. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am. 2008;34:89-114.
7. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin N Am. 1996;22:765-81.
8. Kaheleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum. 1995;38:1-4.
9. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature. 2005;436:193-200.
10. Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298:1959-64.
11. Weinstein BM. Vessels and nerves: marching to the same tune. Cell. 2005;120:299-302.
12. Eichmann A, Le Noble F, Autiero M, Carmeliet P. Guidance of vascular and neural network formation. Curr Opin Neurobiol. 2005;15:108-15.
13. Suda K, Guo C, Oishi A, Ikeda S, Uemura A, Yoshimura N. Therapeutic potential of semaphorin 3E for the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2014;55:4700-6.
14. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature. 2003;424:391-7.
15. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 2004;64:1008-115.
16. Eichmann A, Makinen T, Alitalo K. Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev. 2005;19:1013-21.
17. Derijck AA, Van Erp S, Pasterkamp RJ. Semaphorin signaling: molecular switches at the midline. Trends Cell Biol. 2010;20:568-76.
18. Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science. 2005;307:265-8.
19. Gelfand MV, Hong S, Gu C. Guidance from above: common cues direct distinct signaling outcomes in vascular and neural patterning. Trends Cell Biol. 2009;19:99-110.
20. Serini G, Napione L, Arese M, Bussolino F. Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovasc Res. 2008;78:213-22.
21. Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol Cell Biol. 2010;30:3086-98.
22. Brown FD, Rozelle AL, Yin HL, Balla T, Donaldson JG. Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol. 2001;154:1007-17.
23. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;15:557-67.
24. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;15:1953-62.
25. Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res (Hoboken). 2011;63:142-9.
26. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364:603-10.
27. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988;15:202-5.
28. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013;2013:2737-47.
29. Scott PA, Bicknell R. The isolation and culture of microvascular endothelium. J Cell Sci. 1993;105:269-73.
30. ImageJ. http://rsbweb.nih.gov/ij.
31. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando Randone S, Conforti ML, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109:e14-26.
32. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-4.
33. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis. 2008;4:241-6.
34. De Smet F, Segura I, De Bock K, Hohensinner PJ, Carmeliet P. Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol. 2009;29:639-49.
35. Adams RH, Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol. 2010;2:a001875.
36. Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud's syndrome: a randomized trial. Lancet. 1999;354:1670-5.
37. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999;221:312-5.
38. Herrick AL, Clements PJ, Furst DE. Nervous system In Systemic sclerosis. 2nd ed. Philadelphia: Williams & Wilkins; 2004. p. 309-17.
39. Raper JA. Semaphorins and their receptors in vertebrates and invertebrates. Curr Opin Neurobiol. 2000;10:88-94.
40. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274:1123-33.
41. Ibba-Manneschi L, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum. 2006;54:202-13.